CD4 and neoplasm: For instance, BRAF-MEK inhibition can activate GSDME-dependent pyroptosis to enhance the immune recognition of melanoma cells, including an increase in CD4+ T cell and CD8+ T cell infiltration and a decrease in myeloid-derived suppressor cells (MDSCs) and tumor-associated macrophages (19–21).